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Attention-deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed 
neurodevelopmental disorder, characterized by persistent inattention and/or hyperactivity-
impulsivity that are inappropriate for one’s developmental stage. Individuals with ADHD 
suffer from adverse outcomes including somatic and psychiatric comorbidities. ADHD is also 
associated with increased risk of factors that may impose higher mortality risks. However, 
evidence has been limited on the association between ADHD and somatic diseases such as 
asthma. Also, the association between ADHD and premature death, as well as the potential 
effects of ADHD medication treatment is largely unknown.  
The overarching aim of this thesis is to investigate the associations between ADHD and 
specific adverse outcomes including asthma and premature death. Individual studies were 
conducted to clarify the magnitude and etiology of the associations, as well as potential 
effects from medication treatment that may prevent poor prognosis. 
In Study I, we combined a meta-analysis of existing studies and a Swedish national 
population-based analysis to investigate the population-level association between asthma and 
ADHD. In the meta-analysis, we found a significant cross-sectional association between 
asthma and ADHD when considering both unadjusted and adjusted odds ratios. The sub-
group and meta-regression analyses showed consistently robust results across study settings. 
Estimates of the association from the Swedish population analysis were similar with the 
pooled results from the meta-analysis, and the association remained statistically significant 
after adjustment of potential confounders in the population-based analysis. 
In Study II, we investigated the familial liability to the comorbidity between asthma and 
ADHD. In the familial co-aggregation analysis, relatives of individuals with asthma had an 
increased risk of ADHD compared to relatives of individuals without asthma. The association 
was strongest in monozygotic twins and attenuated with decreasing degree of genetic 
relatedness. Results from the twin modelling analysis supported that a substantial part of the 
association between asthma and ADHD was explained by genetic factors. Estimates for 
contributions from shared and non-shared environment factors were not statistically 
significant. 
In Study III, we investigated the all-cause and cause-specific mortality risks in ADHD and 
the role of psychiatric comorbidity. We found that ADHD was associated with significantly 
increased all-cause and cause-specific mortality risks, with suicide and unintentional injuries 
being the leading causes of death. Psychiatric comorbidity largely mediated the elevated 
mortality risks in ADHD, as the mortality risks increased substantially with the number of 
comorbid psychiatric disorders. Early-onset disorders such as conduct disorders contributed 
substantially to the association for natural deaths, while later-onset disorders such as 
substance use disorders may have mediated most of the risk for unnatural deaths in ADHD. 
In Study IV, we investigated how ADHD medication initiation and continuation associated 
with mortality risks among individuals with ADHD. During follow-up to a maximum of 2 
years, the mortality rates due to any cause and unnatural causes were significantly lower 
among those who initiated medication treatment compared to those who had not initiated 
medication. Among individuals who had been on ADHD medication for up to 6 months after 
diagnosis, continuation of medication treatment was significantly associated with 
substantially lower all-cause and unnatural cause-specific mortality risks including suicide 
and unintentional injuries compared to discontinuation. 
In summary, results of Study I and II together support the significant association between 
asthma and ADHD. The comorbidity may largely be explained by shared etiology, with 
substantial influences from shared genetic factors. The findings also point out shared genetic 
factors as an important direction to understand the mechanisms of adverse conditions related 
to ADHD other than asthma. Study III and IV together reveal that ADHD is associated with 
significantly increased all-cause and cause-specific mortality risks, and ADHD medication 
treatment may help to reduce the risks. The findings point out medication treatment as a 
promising way to prevent extremely severe adverse outcomes among individuals with 
ADHD. 
In conclusion, findings from this thesis work support that individuals with ADHD are at 
increased risk of adverse outcomes including somatic conditions such as asthma and severe 
adversities such as premature death. Shared genetic factors largely explained the association 
between asthma and ADHD, indicating the significance of detecting within-individual and 
family history of either disorder for preventing delayed diagnosis of the other condition. 
Moreover, psychiatric comorbidities and medication treatment play crucial roles in 
understanding the mechanisms of ADHD associated mortality risks and in preventing 
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1.1 ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) 
1.1.1 Origin of ADHD 
The first reference of the disorder can trace back to the year of 1775, when a Germany 
physician described a syndrome of “attention deficit”.1 It was until 1980 when reliable 
diagnostic criteria were available in the revised third edition of Diagnostic and Statistical 
Manual of Mental Disorders (DSM-III-R).2 Since then, numerous clinical and research efforts 
have revealed that ADHD is a highly prevalent and persistent disorder. 
1.1.2 Clinical diagnosis 
Currently both DSM and the International Classification of Diseases (10th edition; ICD-10)3 
are used for clinical diagnosis of ADHD. Clinical diagnosis of ADHD requires assessment of 
the symptoms, considering the severity and lasting time (usually more than 6 months) of 
functioning impairment manifestations, as well as developmental age of the individual.4 
Both DSM and ICD classifications evaluate whether the afflicted individuals present 
developmentally inappropriate and impairing levels of inattention, hyperactivity and 
impulsivity with childhood onset and impairments to school/social performance, and 
intellectual and occupational functioning.5,6 When assessing ADHD symptoms, information 
from several informants is typically needed, and the patients themselves, parents, and school 
teachers have been shown to provide valuable information.7 Clinicians also need to consider 
the age of the patient, and the age-of-onset of the symptoms are also important when deciding 
on whether a clinical diagnosis is appropriate, because the presentation of symptoms may 
change across age,7,8 The DSM-IV classification system is less restrictive when identifying 
ADHD compared to the ICD-10 where the disorder is described as hyperkinetic disorder 
(HKD).9 The DSM-IV also define three subtypes of ADHD based on symptoms, including 
primary inattentive, primary hyperactive-impulsive, or combined,10 which are not available in 
ICD-10. 
The fifth edition of DSM (DSM-5) published in 20137 introduced profound changes 
regarding diagnosis of ADHD. For example, instead of defining three subtypes, DSM-5 now 
uses the term “presentation”, to acknowledge the heterogeneity of the behavioral 
manifestations of ADHD in different developmental stages.11 Another significant change was 
to the age-of-onset criteria from 7 to 12 years old, which may affect the subsequent estimates 
of prevalence. Moreover, ADHD usually persists into adulthood, with substantially 
heterogeneous presentations across age.8,12,13 Accordingly, DSM-5 decreased the threshold of 
symptoms for diagnosis in cases older than 17 years old, from six symptoms in DSM-IV to 
five in DSM-5. Diagnosis of ADHD in adults also requires evidence of symptoms and 
corresponding functioning impairments, as well as possible age of onset. Information source 
can be the patient through clinical interview, and close informants if possible.14 
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Recently, the ICD-11 was published with noticeable updates of terminology and diagnostic 
criteria for ADHD.15 In short, ADHD is now included in the category of neurodevelopmental 
disorders, described with inattentive and hyperactive/impulsive presentations without defined 
age of onset and duration of symptoms. Such updates helped bring the DSM-5 and ICD-11 
systems more consistent in defining symptoms and diagnostic criteria for ADHD,16 which 
may facilitate the generalizability and communication of both clinical practice and relevant 
research on the disorder in different countries.17 
Standardized scales are available to help collect information from the patients or informants. 
Although not accurate enough to estimate the onset age of ADHD, studies have reported that 
parent-rated questionnaires are valuable in early identification and treatment decision making 
among children.18 Rating scales for adults such as Conners’ Adult ADHD Diagnostic 
Interview19 and the Adult Self-Report Scale 20 have also been shown reliable in structured 
diagnostic interviews for both the patients and informants. 
1.1.3 Epidemiology 
The prevalence of ADHD among children has been estimated to be around 5% 
worldwide.21,22 Results from meta-analysis indicate substantial variation in the prevalence 
across studies, primarily due to different diagnostic criteria (DSM vs. ICD), information 
source (patient vs. informants), and requirement of functional impairments.4,9 For example, 
North America uses DSM classification as the diagnosis tool, but European countries 
commonly use ICD system, which has relatively more restrictive criteria for ADHD 
diagnosis. In a recent meta-analysis, ADHD prevalence became stable across geographical 
regions and populations after adjusting for these factors.23 Moreover, there has been no 
significant increase in ADHD prevalence during the past three decades, worldwide, 
regardless of concerns about the issue of over-diagnosis recently with improved awareness.24 
ADHD affects around 2.5% of adults in the world.25-27 Prevalence of ADHD among adults 
substantially depends on how ADHD persistence into adulthood is defined, following the 
childhood onset of the disorder.8 Many of the children with a diagnosis of ADHD may not 
meet the full criteria of ADHD in their adulthood, in part due to a decline in symptoms across 
age.12 However, almost two-thirds of ADHD cases with childhood diagnosis persistently 
suffer from relevant impairments in adulthood.8,28 Due to the corresponding updates in DSM-
5, more details are available to describe ADHD in adulthood, where the diagnosis criteria 
among adults became more inclusive.7 Studies reported that such updates resulted in a 
slightly increased prevalence of ADHD among young adults, from 2.8% using DSM-IV to 
3.5 % using DSM-5.29 It is not known how the recently published ICD-11 would affect 
ADHD prevalence among adults, but no specific descriptions of ADHD symptoms or 
impairments in adulthood were provided.30 
Studies have shown that the prevalence of ADHD differs substantially across sex, especially 
among children with boys accounting for almost two-thirds of the identified young ADHD 
cases.21,31 Although the sex discrepancy largely attenuates in adulthood, it may be due to 
possible referral bias. Girls and adult women with ADHD are less prone to seek for 
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professional help and treatment compared to their male peers; diagnosed female ADHD cases 
usually present relatively more severe symptoms or pertaining impairments.32,33 Socio-
economic status within a population and ethnicity are among other factors that researchers 
suggested may affect the incidence or prevalence of ADHD, with arguments of health 
resource accessibility or cultural stigma.34-37 However, inconsistent evidence exists and it is 
unclear if such factors affected incidence of ADHD or if ADHD itself leads to the risk of 
lower socio-economic status in the family.38  
1.2 ETIOLOGY OF ADHD 
ADHD is etiologically a multifactorial disorder influenced by both genetic and environmental 
risk factors.9,39 Each of the risk factors may have limited effects, and accumulation of effects 
from many different factors build up to the general susceptibility, where both additive and 
interactive reactions between factors may exist.4 The multifactorial causation of ADHD leads 
to heterogeneity of clinical manifestations and prognostic outcomes. Meanwhile, because no 
single factor has been determined to cause ADHD independently from other factors, 
diagnosis and prevention efforts targeting specific risk factors may end up with limited 
efficacy. 
1.2.1 Genetic susceptibility 
Familial aggregation is common regarding incidence of ADHD, with parents and siblings of 
ADHD probands presenting 5-10 times higher risk of developing the disorder compared to 
the general population.40-42 Family and twin studies have reported heritability of ADHD as 
high as 70%-90%.42-44 Single Nucleotide Polymorphism (SNP)-based heritability for ADHD 
symptoms range from 5% to 34%, indicating substantial influence from common genetic 
variants on ADHD symptom scores and possibility of polygenic correlation.45  
Approximately 40% of the heritability of ADHD estimated from genome-wide association 
studies (GWAS) can be attributed to common genetic variants.46 Additionally, rare genomic 
insertions and deletions, known as copy number variants (CNV), also affects ADHD.47-49 
Researchers suggested that potential candidate genes involved in the monoamine 
neurotransmitter systems are related to ADHD.50 For example, the SLC6A3 gene encoding 
dopamine transporters may also affect ADHD, based on potential pathophysiology of ADHD 
where stimulant drugs acting on these dopamine transporters alleviate ADHD symptoms. 
Several GWAS analyses supported that the group of genes regulating the dopamine, 
noradrenaline, serotonin, and neurite outgrowth systems associates with ADHD and 
symptoms of hyperactivity or impulsivity.51-53 Recently, a GWAS meta-analysis covering 
20 183 ADHD cases and 35 191 controls identified 12 independent loci with genome-wide 
significant association with ADHD for the first time.54 Findings from this study furtherly 
indicated the significant influence of common genetic variants in the polygenic architecture 
of ADHD. Moreover, several of these 12 loci relates to genes influencing 
neurodevelopmental process. 
1.2.2 Environmental factors 
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Perinatal exposures to adverse conditions may predispose the risk for ADHD. Complications 
suggested in previous studies included toxemia, poor maternal health during pregnancy, 
maternal age at birth, long duration of labor, fetal distress, and antepartum hemorrhage.55-57 
Maternal smoking and alcohol use, and exposures to other environmental toxins during 
pregnancy such as organophosphate pesticides, polychlorinated biphenyls, zinc and lead are 
also potential risk factors for ADHD.58,59 Effects of each environmental factor are relatively 
small and usually accumulate to increase the overall risk.9,58 In addition, psychosocial 
adversity has also been a major suspected factor regarding the risk of developing ADHD. 
Rutter’s index of adversity incorporated six risk factors describing adverse family 
environment including severe marital discord, low social class, large family size, paternal 
criminality, maternal mental disorder, and foster placement.60 Population-based studies 
revealed that the Rutter’s index was positively correlated not only with ADHD, but also with 
ADHD associated psychopathology, impaired cognition, and psychosocial dysfunctions.61,62 
1.3 TREATMENT OF ADHD 
The European clinical guidelines for management of ADHD (hyperkinetic disorder) defined a 
hierarchal model, where psychological interventions, educational change, medication and 
dietary measurements are integrated.63 Non-pharmacological treatments include mainly 
educating the parents or behavioral interventions toward both parents and ADHD patients.64 
Efficacy of behavioral approaches is relatively good, and combination therapy together with 
ADHD medication treatment may predict better prognosis.65,66 Results from meta-analyses 
have reported that dietary approaches including supplement or exclusion of specific food can 
have potentially beneficial effects,67 but the effects were limited to small subgroups of those 
with ADHD.   
Pharmacological treatment including stimulant and non-stimulant medications are 
recommended for individuals diagnosed with ADHD in clinical guidelines for both children 
and adults.68-74 The first regulatory approval of stimulant treatment among children with 
ADHD was issued in 1960s.75 Since then, prescription of medications has been increasing 
globally and stimulants (mainly methylphenidate and amphetamine) have been the 
predominant choice for clinical treatment of ADHD.76,77 Stimulants can improve 
neurotransmission of dopamine and norepinephrine,78 which is involved in the 
pathophysiology of ADHD. Non-stimulants, mainly represented by atomoxetine (selective 
noradrenaline reuptake inhibitor), clonidine and guanfacine (long-acting α2-adrenergic 
agonists), are also effective alternatives.79-81 Choice of medication depends on clinical 
severity and presentation of symptoms, as well as comorbid somatic and psychiatric 
conditions. Specific treatment intentions concerning different situations are also important, as 
medications with transient vs. relatively long-lasting effects are now available.82 
1.4 ADVERSE OUTCOMES OF ADHD 
1.4.1 Somatic comorbidity in ADHD: association and etiology 
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Classically defined nervous system disorders are now also thought to include alterations in 
other physiological systems.83 This notion has prompted research into the possible 
associations between neuropsychiatric and somatic conditions. Relatively poorer health status 
with comorbid somatic conditions such as obesity and asthma were more common in ADHD 
cases compared to individuals without the disorder.84 However, evidence on somatic 
comorbidities in ADHD is largely limited and potential mechanisms underlying most of the 
observed comorbidities remain unclear. 
Obesity is one of the most investigated somatic conditions associated with ADHD. Meta-
analyses of population-based studies reported around 30% elevated risk of 
obesity/overweight associated with ADHD, with the hypothesized mediating effects of 
abnormal eating habits or sedentary lifestyle.85-87 A later study on Swedish national register 
data found that ADHD and obesity co-aggregate in families, and the comorbidity between the 
two conditions can be entirely attributed to shared genetic factors.88 Combined results from 
the general population and the family data indicate that the association between ADHD and 
obesity may be etiologically attributed to the same genetic factors underlying both conditions. 
Moreover, the possible mediation effects from poor eating behavior was supported by a 
recent twin study identifying weak genetic overlaps of inattention with high-sugar food 
(genetic correlation 0.16; 95% CI, 0.07-0.25) and hyperactivity/impulsivity with unhealthy 
dietary pattern (genetic correlation 0.05; 95% CI, −0.05-0.14), respectively.89 But the twin 
study was based on symptoms of ADHD measured from questionnaire survey and self-
reported eating behavior. Further studies are needed to clarify the causality between 
clinically diagnosed ADHD and eating disorders, with consideration of obesity as the 
endpoint outcome. 
Asthma is the most prevalent chronic respiratory disease, affecting around 3-5% children in 
low-income countries and as high as 20% in high-income countries.90 An association between 
asthma and ADHD has been tested in clinical and population data, with the hypothesis 
originating from a possible link between ADHD and allergic or atopic diseases such as 
eczema.91 Specifically, the two main hypotheses causally linking asthma and ADHD were 
that 1) children with asthma experiencing excessive stress from peer and parents lead to 
ADHD related alterations in the brain; and/or 2) that the hyper-secretion of pro-inflammatory 
cytokines from allergic reactions pass through the blood-brain barrier and affect the prefrontal 
cortex which is closely related to the pathophysiology of ADHD.92-94 However, findings from 
previous studies were not conclusive for either the existence of the association or the potential 
mechanisms underlying such comorbidity. An early meta-analysis including five cross-
sectional studies reported a significant association between ADHD and asthma, but the 
included five studies were with low quality and the authors only pooled unadjusted odds ratio 
(OR) of 1.80 (95% CI, 1.57-2.07).95 Another meta-analysis of six longitudinal studies found 
that early asthma imposed over 30% increased risk of later ADHD onset, but there were 
overlapping samples across studies and representativeness of the samples were not clear.96 
More importantly, previous studies have not fully addressed if the reported association is due 
to potential confounders. Therefore, the hypothesis of a significant association between 
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asthma and ADHD awaits rigorous testing. Moreover, it remains to be investigated if the 
comorbidity of asthma and ADHD is explained by shared etiology or direct causality between 
the two disorders. Recently, a large genome-wide association meta-analysis54 of ADHD 
reported a small genetic correlation with asthma, but the extent to which these findings 
replicate in family and twin data remains unclear. Once a robust association is established 
between asthma and ADHD, large-scale family co-aggregation studies incorporating 
quantitative genetic modelling analysis can be substantially informative for both causally 
understanding the association and clinically improving early detection of ADHD in asthmatic 
children or vice versa. 
1.4.2 Psychiatric comorbidity in ADHD: association and etiology 
Symptoms and impairments are heterogeneous among individuals with ADHD.4,16 A small 
subgroup (around 13%-30%) of individuals with ADHD do not have any comorbid 
psychiatric disorders,97 whereas the majority may suffer from multiple problems. Literature 
reviews and meta-analyses reported elevated risk of both internalizing and externalizing 
disorders in individuals with ADHD, and the link was usually observed to be bi-directional 
from observational data.98-103 Specifically, conduct disorders (CDs) and oppositional defiant 
disorder (ODD) are among the most commonly identified comorbidities, as 45-65% of 
children with ADHD were also diagnosed with ODD and half of the children with such 
comorbidity may progress to CDs.104,105 ADHD also associates with other 
neurodevelopmental disorders including autism spectrum disorders (ASD)106-108 and 
intellectual disability (ID).109 For example, different studies reported that 31-95% of children 
with ASD presented ADHD like symptoms including inattention and 
hyperactivity/impulsivity,110 and about 20-50% of children with ADHD also met the 
diagnostic criteria for ASD.111  ADHD in childhood predicts later substance use disorders 
(SUD), as meta-analyses of cohort studies reported that compared to their peers without 
ADHD, children with the disorder presented around doubled risks of developing misuse or 
dependence of substances including alcohol, nicotine and marijuana in adolescence or early 
adulthood.112,113 Another meta-analysis revealed that about one in every four adolescents and 
adults with SUD met the DSM criteria for ADHD.114 Studies found that approximately 20% 
(ranging from 10% to 35%) of children with anxiety also had ADHD; and 50% of children 
with ADHD suffered from anxiety.115 Similar levels of co-occurrence were present for 
ADHD and mood/affective disorders, as well as bipolar disorders.97 Risk of developing major 
depressive disorders was over five times higher among youth with ADHD than youth 
without.116 Moreover, evidence supports associations between ADHD and eating 
disorders117,118 and personality disorders,119,120 although pooled associations from meta-
analysis have been limited. 
The underlying mechanisms of the comorbidity between ADHD and other psychiatric 
disorders are not totally established yet. Genetic factors may play a crucial role in 
understanding the psychiatric comorbidity of ADHD. Sibling and twin based studies 
identified a general genetic factor influencing the co-occurrence of neurodevelopmental 
disorders including ADHD and internalizing and externalizing problems.121 The findings 
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indicate that common psychiatric disorders including ADHD may share the same genetic 
origins. Familial co-aggregation studies between ADHD and other psychiatric disorders 
including ASD, SUD, anxiety, depression, and personality disorders also support that shared 
familial liability mostly contributed from genetic factors may largely explain the 
comorbidity.108,109,122-128 A meta-analysis summarized similar magnitudes of pooled genetic 
correlations between ADHD and externalizing problems (0.49 [95% CI, 0.37-0.61]), 
internalizing problems (0.50, [95% CI, 0.44-0.56]), and neurodevelopmental disorders (0.56, 
[9.% CI, 0.47-0.66]).129 The recent GWAS reported 12 loci of genome-wide association with 
ADHD and provided insights into understanding the links between ADHD and other 
psychiatric disorders.54 For example, among the identified genetic variants, the FOXP2 
located on chromosome 7 may influence the comorbidity between ADHD and intellectual 
disability (ID), and the SORCS3 on chromosome 10 were previously reported to be associated 
with neurodevelopmental disorders and depression. Environmental factors may also explain 
part of the psychiatric comorbidities in ADHD. For instance, children with ADHD may 
develop depression several years after the onset of ADHD, as a result of excessive pressure 
from peers or parents.116 A related hypothesis is that although ADHD and depression may 
share the same familial liabilities, the heterogeneity in symptom spectrums and severity 
across patients is mainly driven by non-shared environmental factors unique to the individual. 
Moreover, sex differences in the relative risks and patterns of psychiatric comorbidities were 
found in previous studies. An early study from Denmark found that girls with ADHD had 
higher risk of multiple psychiatric disorders in adulthood compared to boys with ADHD.130 A 
recent study using the Danish national registers with a much larger sample found that females 
with ADHD presented higher risk of developing ASD, CD/ODD, ID, SUD, and personality 
disorders. 
1.4.3 Preventing adverse outcomes in ADHD 
Individuals with ADHD have poorer quality of life, and are at increased risk of multiple 
adversities including morbidity and mortality. Somatic and psychiatric comorbidities may be 
important contributors to the overall risk of adverse outcomes in ADHD, and can also 
provide significant clues of preventing specific adversities with better understanding of the 
etiology underlying the comorbidities. For instance, establishment and awareness of the link 
between asthma and ADHD could prompt asthma specialists to refer asthmatic children with 
ADHD-like symptoms to specialists for early diagnosis of ADHD and encourage 
psychiatrists to refer ADHD cases with early signs of asthma. Delayed diagnosis has been a 
big issue for both asthma and ADHD, and early diagnosis and management can substantially 
alleviate adverse outcomes.16,131,132 Furthermore, direct causality between the two disorders 
can provide clear directions of preventing both conditions; shared causality, apart from 
emphasizing the importance of family history when considering clinical referral as mentioned 
above, can also improve the research into the links between ADHD pathophysiology and 
allergic conditions at large. 
Individuals with ADHD are prone to higher risks of adverse outcomes including 
criminality,133 accidents,134,135 and suicidal behavior.136-139 Potential additive or mediating 
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effects of psychiatric comorbidity are often among the most mentioned hypotheses for 
possible mechanisms. On the other hand, various psychiatric disorders such as SUD and 
depression were associated with increased risk of premature death, especially due to 
unnatural causes including suicide.140-142 However, evidence has been limited how ADHD 
directly associates with premature death, and how various types of psychiatric comorbidities 
affect the association. For example, as ADHD onsets early in childhood, it may be reasonable 
to hypothesize that ADHD predisposes increased risk of developing depression in 
adolescence or adulthood, and then leads to higher susceptibility of committing suicide later 
in life. Potential mediation effects from psychiatric comorbidities are possible, so as for 
additive effects or interactions with having ADHD. A Danish register-based study found a 
two-fold increased risk of all-cause mortality in ADHD, with majority of deaths due to 
unnatural causes in the ADHD group.143,144 The mortality rates were higher among 
individuals with co-occurring CD/ODD, and/or SUD, supporting the additive or mediating 
mechanisms of psychiatric comorbidity. However, the authors did not have the power to 
explore cause-specific mortality risks and missed exploration of the possible effects from 
different types of psychiatric comorbidities. Investigation of the overall mortality risks in 
ADHD and exploration of the potential effects from psychiatric comorbidities can 
substantially facilitate identification of high-risk groups in clinical practice, and prioritization 
of resources for preventing premature deaths. For instance, if specific types of psychiatric 
comorbidities impose the most contribution to the excessive mortality risks in ADHD, more 
efforts could be prioritized clinically in early identification and proper management of such 
comorbidities.  
A recent meta-analysis145 evaluating efficacy of medications concluded that methylphenidate 
in childhood and amphetamines in adulthood present good tolerability and treatment effects. 
A review study mentioned potential side effects from ADHD medication treatment, including 
sleep problems, decreased appetite, and suppressed growth of height in childhood.4 More 
severe outcomes including adverse cardiovascular events and sudden death were mentioned, 
but existing evidence do not predominantly indicate causal relationships between the 
medication use and observed outcomes.146-148 On the contrary, multiple studies reported the 
potentially beneficial effects of medication treatments on both ADHD symptoms and related 
problems.149 Potential benefits from ADHD medication were reported on adversities such as 
suicide,150,151 accidents,134,135 and SUD.152-154 However, it is largely uninvestigated how 
ADHD medication treatment affects the risk of premature death among individuals with 
ADHD. More specifically, it remains unknown if ADHD medication treatment initiation and 
continuation would affect the all-cause and cause-specific mortality risks. Further research 
into the potential effects from ADHD medication treatment on adverse outcomes such as 
cause-specific premature deaths can provide both clinical and public health implications in 




2.1 OVERARCHING AIM 
To investigate the association between ADHD and adverse outcomes including asthma and 
premature death, with focus on investigating the mechanisms underlying the associations and 
potential treatment effects to prevent the adversities. 
2.2 SPECIFIC AIMS 
Study I: To summarize existing evidence on the population-level association between asthma 
and ADHD using meta-analysis and to validate the association in a Swedish population-based 
analysis. 
Study II: To investigate patterns of familial co-aggregation of asthma and ADHD and also to 
quantify the relative contribution of genetic and environmental influences. 
Study III: To investigate the all-cause and cause-specific mortality risks in ADHD and to 
explore the potential role of psychiatric comorbidities. 
Study IV: To investigate how initiation and continuation of ADHD medication associate with 




3 DATA SOURCES AND MEASURES 
3.1 DATA SOURCES 
We have linked several Swedish national registers using the unique personal identification 
numbers (PINs). Since 1947, every resident in Sweden was assigned with a unique ten-digit 
PIN which is used by Swedish governmental agencies for the purpose of administration and 
linkage through different national registers.155 Data of this thesis was extracted mainly from 
the following nationwide registers. 
Medical Birth Register (MBR), initiated from 1973, consists records of nearly all births in 
Sweden with information on perinatal status.156 
National Patient Register (NPR), contains information of all inpatient discharges since 
1987 and specialist outpatient care since 2001, with diagnoses coded according to the 
Swedish version of International Classification of Diseases 10th revision (ICD-10; from year 
1997).157  
The Prescribed Drug Register (PDR) has complete coverage of dispensed medications in 
Sweden since July 2005, coded according to the Anatomical Therapeutic Chemical (ATC) 
classification system.158 The PDR does not include information on medications used during 
hospitalization. 
The Swedish Twin Registry (STR), established in 1950s, includes questionnaire survey 
information on almost 200 000 twins born in Sweden since 1886.159 
The Longitudinal Integration Database for Health Insurance and Labor Market 
Studies (LISA) since 1990 keeps census information including employment and highest 
completed education of all individuals aged 16 or older.160 
The Cause of Death Register (CDR) initiated in 1952 provides information on dates and 
causes of all deaths in Sweden. Causes of death were coded by the ICD systems.161 
The Multi-Generation Register (MGR) covering people born after 1932 in Sweden was 
used to identify parents to cohort members, and the Migration Register was linked to account 
for all emigrations from Sweden.162 
3.2 MAIN MEASURES 
3.2.1 ADHD 
Two sources of information from the Swedish registers can be used for ADHD definition. 
Clinical diagnosis records of ADHD according to the ICD systems (ICD-9: 314; ICD-10: 
F90) from NPR are used to define ADHD in Study I and Study II when investigating the 
comorbidity between asthma and ADHD. In Study III, ADHD was identified by first 
diagnosis from NPR or the first prescription of ADHD medications (methylphenidate 
hydrochloride [ATC code N06BA04], amphetamine [ATC code N06BA01], 
dextroamphetamine sulfate [ATC code N06BA02], and atomoxetine hydrochloride [ATC 
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code N06BA09]) from PDR. In Study IV, we identified individuals with ADHD by the NPR 
diagnosis. 
3.2.2 ADHD medication treatment 
In Study IV, information on prescribed medication and dosage was extracted from PDR to 
define the treatment periods of ADHD medication. Treatment periods from each prescriptions 
were estimated from the prescriber’s free-text prescription using a validated algorithm.163 
Natural language processing models were developed to extract information from each free-
text prescription and to predict daily dosage and treatment duration, taking into account 
features including titration, stockpiling and non-perfect adherence. 
3.2.3 Asthma 
In Study I and II, asthma was defined as clinical diagnosis after three years old (ICD-9 code 
493 or ICD-10 code J45–J46) from NPR or prescriptions of asthmatic medications (ATC 
codes R03AC, A03AK, R03BA, and R03DC) from PDR.164 
3.2.4 Psychiatric comorbidity 
In Study III and IV, we identified diagnosis of psychiatric comorbidities with ADHD from 
NPR. The ICD-10 codes for each psychiatric disorder is presented in Table 3.2.4. In Study 
III, we further categorized these psychiatric comorbidities into two groups according to the 
relative diagnosis age to ADHD in our data. 
Psychiatric and behavior disorders ICD-10 codes Category for analysis 
Autism spectrum disorders (ASD) F84 Early-onset disorder 
Intellectual disability (ID) F7x Early-onset disorder 
Conduct disorders (CD/ODD) F90.1, F91 Early-onset disorder 
Eating disorders (ED) F50.0-F50.3, F50.9 Later-onset disorder 
Substance use disorders (SUD) F10-F16, F18-F19 Later-onset disorder 
Depressive disorders (Dep) F32-F34 Later-onset disorder 
Bipolar disorders (Bip) F30-F31 Later-onset disorder 
Anxiety disorders (Anx) F40-F41 Later-onset disorder 
Schizophrenia (SCZ) F2x Later-onset disorder 
Personality disorder (PD) F60-F62, F69 Later-onset disorder 
Table 3.2.4 ICD-10 codes for diagnosis of psychiatric comorbidities. 
3.2.5 Other psychotropic medication 
Prescription records of psychotropic medications other than ADHD medications were 
identified from PDR, including antipsychotics [ATC code N05A]; anxiolytics, hypnotics, and 
sedatives [ATC code N05B or N05C]; antidepressants [ATC code N06A]; antiepileptic drugs 
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[ATC code N03A]; drugs used in addictive disorders [ATC code N07B]; and opioid pain 
medications [ATC code N02A]. The information was used as additional identification of 
psychiatric comorbidities in Study III, and baseline covariates in Study IV. 
3.2.6 Premature death 
Both all-cause and cause-specific premature deaths were used as outcomes in Study III and 
IV. Specific causes of death consisted of natural causes, including somatic diseases and 
medical conditions (ICD-10 codes A00-R99), and unnatural causes, including un- intentional 
injuries (ICD-10 codes V00-X59), suicide (ICD-10 codes X60-X84 and Y87.0), and other 
external causes (ICD-10 codes S00-T98 and X85-Y98, excluding Y87.0). In the analysis, 





4.1 CAUSAL INFERENCE FROM OBSERVATIONAL STUDIES 
The scope of epidemiological research covers both describing features of a health-related 
issue and linking specific factors with the outcome of interest.165 For the latter, a causal link 
can be hypothesized and tested via either interventional settings such as conducting 
randomized controlled trials (RCTs) where certain factors can be manipulated or 
observational settings such as conducting analysis on population-based datasets. In an RCT, 
eligible subjects are randomly assigned into different groups with or without the intervention 
of interest, and inferences can then be made by comparing outcome incidences across 
different groups. Subjects across different intervention groups are exchangeable regarding 
baseline features. Since the only difference across groups is the intervention factor, given 
proper sample size and adherence, RCTs can serve as the highest level of evidence for 
investigating whether the factor of interest can cause the outcome under research.166 
However, significant limitations of RCTs including potential ethical issues, high costs of 
practicality, unpredictable adherence, and exclusion of severe cases substantially impede the 
feasibility and generalizability of RCTs to answer many important research questions.167,168 
Observational data may be obtained through a survey on a sample of the pre-defined 
population, or acquired through access to existing population data such as the national 
register linkage or insurance claim datasets. Although with the risk of potential biases and 
measurable/unmeasurable confounding, proper design and analysis plan can largely facilitate 
the understanding of causality, making observational study an important alternative approach 
to RCTs, with applications such as in identifying risk factors for a health condition or 
analyzing treatment effects on prognosis.169,170 
4.1.1 Directed acyclic graph 
Causality can be inferred from observation studies, but never from observed associations 
without proper design to avoid biases or adjustment of factors that may affect both the 
exposure and the outcome. Ideally, possible confounders should be identified based on 
available knowledge before conducting the study, so that both measured and unmeasured 
confounding can be dealt with to the largest extent from the beginning. Using existing 
evidence and knowledge, researchers could use directed acyclic graphs (DAGs) to illustrate 
the possible causal pathways from the exposure to the outcome, incorporating relevant 
covariates to the causal pathway.171,172 These covariates may be categorized into potential 
confounders (common causes of the exposure and outcome), mediators (covariates lying on 
the causal pathway), and colliders (common results of the exposure and outcome), illustrated 
using directed arrows in the DAG(Figure 4.1.1). Consequently, unmeasured confounding can 
be addressed in the study design stage, such as accounting for genetic confounding by family-
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based designs;173 measured confounding can be dealt with by adjustment in statistical 
models.174,175 
4.1.2 Genetically informative studies 
4.1.2.1 Application of genetically informative designs 
Genetically informative studies incorporate traditional epidemiological analysis in the 
settings of families or relatives, based on assumptions of known genetic and environmental 
relatedness across family pedigrees. Such designs, given proper sampling and reliable 
measurements, can provide more concrete evidence on understanding the causality 
underlying an observed association from traditional population-based research. Genetically 
informative studies can be conducted to answer various research questions, including 
estimating the broad-sense heritability, clarifying the shared causality for comorbidity 
between diseases, and quantifying the genetic and environmental influences on phenotypes. 
For example, monozygotic (MZ) twins are 100% genetically identical, while dizygotic (DZ) 
twins share 50% of segregating alleles; MZ and DZ twins both share the same familial 
environmental factors as they grow up in the same households. A stronger association 
between an exposure and outcome in MZ twins than in DZ twins may indicate genetic 
influences to the association. 
Analyzing the aggregation (familial aggregation analysis) of a phenotype across family 
pedigrees using quantitative genetic modelling methods provides results in heritability, 
interpreted as how important the genetic background underlies the etiology of this phenotype. 
For example, twin modelling studies have estimated the heritability of ADHD being around 
74%, indicating the significance of genetic predisposition on development of the disorder.121 
When extending the aggregation analysis into two phenotypes (familial co-aggregation 
analysis), researchers could estimate to which extent the familial liability consisting of 
genetic and shared environmental factors underlies an observed association between two 
phenotypes. Moreover, estimates of the non-shared environmental factors (environmental 
factors that are unique to the individual) can shed insights on direct causality between the two 
phenotypes. For instance, a familial co-aggregation study on ASD and ADHD revealed that 
 
Figure 4.1.1 A DAG example. The figure illustrates a simplified causal diagram from exposure (X) 
to the outcome (Y), with a mediator (M) on the causal link, a confounder (U), and a collider (Z). 
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the commonly observed comorbidity between the two neurodevelopmental disorders may be 
explained by shared etiology, as ASD and ADHD co-aggregate in families.176 Another 
common application is to view the familial relatedness as “familial confounding” when 
investigating if the observed population-level association between two phenotypes reflects 
direct causality or can actually be attributed to unmeasured confounding. For example, 
population-based studies reported a stable association between maternal pre-pregnancy body 
mass index (BMI) and offspring ADHD, raising concerns over the effects of maternal obesity 
on causing offspring ADHD. However, the association substantially attenuated to non-
significant when running the analysis among siblings, indicating that the observed association 
on population level may actually be explained by unmeasured confounding.177 
4.1.2.2 Comparative significance with genomics research 
The tremendous development of research on genomic data in the past two decades have 
enabled researchers to understand the development of human traits onto the micro level. 
Genome-wide association studies (GWASs) made it possible to identify individual genetic 
loci underlying specific phenotypes. Consequently, summary statistics data from GWASs can 
also be used in integrated polygenic risk scores (representing the aggregate effects of 
individual genetic loci) in further understanding the etiology of phenotypes or provide 
insights into investigation of biological functions. The largest GWAS on ADHD54 to date 
identified 12 genetic loci with genome-wide significance, and investigated genetic 
correlations between ADHD and 219 phenotypes using summary statistics, with results 
substantially improving the understanding of etiology underlying both ADHD and correlated 
phenotypes. Furthermore, genetic variants can also be used as instrumental variables in 
designs such as Mendelian randomization studies to make causal inferences on an observed 
association, with assumptions that the instrumental variable is independent from potential 
confounding and can thus avoid reverse causation.178 
However, the profound advances and massive application of genomics research may not 
necessarily downplay the significance of population-based genetically informative studies. 
Fundamentally, findings from familial aggregation/co-aggregation analysis and quantitative 
genetic modelling analysis can provide insights and hypotheses for genomics research with 
estimates of relative influences from genetic and environmental factors on specific 
phenotypes. Also, observed familial aggregation of a disorder or co-aggregation of two 
disorders has important clinical implications by emphasizing the necessity of collecting 
information on within-individual and familial history of certain diseases. More importantly, 
the differences of the broad-sense heritability estimated from twin modelling analysis and the 
SNP-based heritability estimated from genomics data (the “missing” heritability problem of 
complex diseases179) have facilitated the understanding and discovery of other genetic factors 
not commonly captured by GWASs such as identification of the rare genetic variants for 
ADHD.121 On the other hand, comparison between the broad-sense heritability and SNP-
based heritability can also imply to what extent common genetic variants have influenced the 
genetic predispositions of a phenotype. 
 
16 
4.1.3 Pharmacoepidemiologic studies 
By definition, pharmacoepidemiology investigates the use and effects of drugs in large 
numbers of people.180 Pharmacoepidemiologic studies suffer less from the practical costs 
compared to RCTs and have the possibility to include patients with various disease severity. 
On the other hand, though, pharmacoepidemiologic studies investigating treatment effects 
may suffer from potential biases and confounding. Observational data can be used to estimate 
potential treatment effects on prognosis using pharmacoepidemiologic designs. However, 
given the limitations of observational data compared to RCTs, proper efforts in study deigns 
and analysis plans should be made to avoid obvious biases and confounding that affect the 
quality of study findings. To begin with, a new user design (individuals who are naïve to the 
medication at cohort entry), excluding prevalent users (individuals who have been on 
medication for a while at cohort entry), should be used.181 Pharmaco-epidemiological studies 
including prevalent users at baseline may suffer from substantial biases. Since prevalent users 
are often “survivors” from early stage of medication use, including them may end up with 
underestimating the risk of events correlated to the initiation stage of treatment, especially for 
medications with time-varying effects. Within-individual analysis can be used for some 
outcomes, where the risk of outcome is compared between treated and untreated periods for 
the same individual to account for conditions constant for the same individual.182 Another 
important effort in pharmaco-epidemiological studies is to emulate a target trial to achieve the 
exchangeability across the treated and untreated groups at baseline.183 Propensity score 
methods are commonly used, where the propensity of getting or not getting the medication 
for all cohort members are calculated based on measured covariates.184-188 The calculated 
propensity score can then be used for matching or model adjustment, as well as inverse 
probability of treatment weighting (IPTW). 
4.2 STUDY DESIGNS 
4.2.1 Cohort studies 
Cohort study is one of the most fundamental study designs in epidemiology, initiated by 
identifying groups of participants according to their status of the exposure, then following 
them for a specific amount of time, and finally comparing the risks of having the outcome 
between the exposed and unexposed groups.165 Clinical trials are special cases of cohort 
studies, where the exposure (intervention) variable is randomly assigned to groups of 
participants that are exchangeable regarding conditions other than the exposure. 
Register-based studies are another group of special cohort study, where the data were usually 
not originally collected for a specific research project. Researchers start by identifying a 
cohort from a defined population (such as a birth cohort or a group of patients diagnosed 
within specific time windows), obtaining relevant information of cohort members via linkage 
through different registers. It is worthwhile to emphasize that the data should be analyzed as 
it is prospectively collected, namely the researchers should not manipulate the cohort or data 
based on conditions that are recorded later than the cohort entry or start of follow-up. 
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4.2.2 Systematic reviews and Meta-analysis 
Systematic reviews summarize the existing evidence on a clearly defined research question, 
and usually offer both qualitative and quantitative assessments of previous findings on the 
research question. The quantitative assessment is usually conducted by a meta-analysis, 
resulting in pooled estimation of included studies. Meta-analysis was first defined by Gene V 
Glass in 1976 as “The statistical analysis of a large collection of analysis results from 
individual studies for the purpose of integrating the findings”.189 In medical science, meta-
analysis, usually incorporated in a systematic review study, has been used as an important 
epidemiological design to systematically summarize and evaluate the quality and quantity of 
existing evidence on a specific topic.190 All possible evidence from published literature are 
searched from databases such as PubMed or Medline. Unpublished results are also acquired 
by direct contact with researchers if needed. After quality control, eligible studies are then 
included in the systematic review for qualitative summary and the meta-analysis to obtain the 
pooled estimates. In evidence-based medicine, summary from meta-analysis ranks the top in 
the hierarchy of evidence, superior than individually conducted RCTs.191,192 In the past few 
decades, publications of meta-analysis studies accumulated dramatically, and standard 
guidelines on reporting meta-analysis such as the Preferred Reporting Items for Systematic 
reviews and Meta-analyses (PRISMA) has been developed and widely adopted by 
researchers.193 Advances in methodology including the development and application of 
network meta-analysis made it possible to compare different exposures or treatment for the 
same topic from separate individual studies.194 
4.2.3 Familial co-aggregation studies 
Familial co-aggregation studies investigate to what extent two traits may cluster within 
families, usually used to explore if there is shared etiology (familial liability) to the observed 
association between the two traits. For example, if relatives of individuals with trait X have 
significantly higher risk of having trait Y, compared to relatives of individuals without trait 
X, it is possible that at least some of the co-occurrence of X and Y can be explained by 
familial liability. The familial liability can then be decomposed to genetic and environmental 
factors by using quantitative genetic modelling analysis. Different relatives such as within-
generation relatives including twins, full- and half-siblings, as well as full- and half-cousins 
or inter-generational relatives such as parent-offspring pairs can be identified from the 
population. A structural approach using DAGs to illustrate and test the potential causal 
pathways between trait X and Y in a familial co-aggregation study was proposed by Hudson 
JI et al.195 This approach have been used to test if there is familial liability causing both traits, 
as well as if the co-occurrence can be more possibly due to direct causality between X and Y 
or other unmeasured confounding.176,196 
4.2.4 Twin studies 
Monozygotic (MZ) twins are genetically identical, and dizygotic (DZ) twins share 50% of 
their segregating alleles; MZ and DZ twins are both assumed to share 100% of common 
environment influences. Based on the above assumptions, twin designs are used to compare 
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the resemblance of one or more traits across twin pairs, and then to estimate the relative 
genetic and environmental influences to a single trait or to the co-occurrence of two traits.197 
For example, based on the measurement of two traits in MZ and DZ twin pairs, one can 
calculate the intra-class (ICCs, correlations of the same trait across twins) and cross-twin-
cross-trait (CTCT, correlations of trait one in sibling one and trait two in sibling two) 
correlations. Bivariate twin modelling can be used to further estimate the relative genetic, 
shared-, and non-shared environmental contributions to the familial liability and to estimate 
the genetic correlation between asthma and ADHD. 
4.3 STATISTICAL METHODS 
4.3.1 Logistic regression 
Logistic regression models are commonly used in cross-sectional studies to estimate the 
potential effects of exposures on a dichotomized outcome, with consideration of other 
relevant covariates.198 The regression coefficient estimated from the model represent the 
change of log-odds for the binary outcome by per unit change in the exposure level, while 
controlling all other covariate levels to be constant. Odds ratios (ORs) can then be calculated 
by taking the exponential of the regression coefficient. ORs are interpreted as comparing the 
odds of developing the outcome among those exposed vs. the odds of developing the 
outcome among those who are not exposed. 
4.3.2 Cox proportional hazard regression 
Cox proportional hazard regression models are generally used in survival analysis on time-to-
event data. Hazard ratios (HRs) are estimated by comparing the hazard functions among 
groups of different exposure levels, assuming that the hazards in the exposed and unexposed 
groups remain proportional within the analysis time. However, it is rarely possible to fulfill 
the assumption of proportional hazards in real-world scenarios, which does not necessarily 
affect the application and interpretation of Cox regression models.199 Cox models does not 
make assumptions on the baseline hazards, and would not estimate the effects of the time 
variable chosen as the underlying time scale (such as attained age). 
4.3.3 Meta-analysis 
The main results in a meta-analysis are usually pooled effect estimates from individual 
studies, in most cases presented in a forest plot including estimates of both individual studies 
and the pooled meta-analysis.200 Studies that meet the qualification criteria are weighted 
based on the inverse of variances so that studies with smaller sample size or greater variances 
contribute less to the pooled estimates.201 The choice of fixed-effect models or random-effect 
models is based on specific research questions and the quality of selected studies. While 
fixed-effect models assume homogeneity across the individual studies regarding the source 
population, sampling criteria and the effects of the exposure or intervention, random-effect 
models accept heterogeneity across studies and results. Random-effect models are more 
frequently used especially in meta-analysis of observational studies since it is rarely expected 
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that all conditions are the same across studies conducted in different settings or populations. 
In addition to the inverse of variance, heterogeneity among study results is also used for study 
weighting in random-effect models. Moreover, quality assessment of the included studies and 
the pooled meta-analysis can be achieved by testing the heterogeneity of studies (for 
example, indicated by the I2 index or through meta-regression), conducting sensitivity or sub-
group analysis of studies that are more homogeneous, and by testing the potential publication 
biases (for example, by conducting the Egger’s test or generating the funnel plots).202-204 
4.3.4 Structural equation modelling 
Structural equation modelling (SEM) is a multivariate statistical method combining factor 
analysis and regression analysis to analyze the structural relationships between both measured 
variables and inferred latent constructs. The method is widely used in quantitative genetic 
modelling analysis such as twin modelling, where additive genetic factors (A), dominant 
genetic factors (D), shared environmental factors (C) and non-shared environmental factors 
(E) are treated as latent components contributing to the total variances of measured 
traits.205,206 Given a trait X measured as a binary variable, the total variance can be 
decomposed by the latent components as in the following equation: 
Xi= + Ai + Di + Ci + Ei 
Xi indicates the measured value of the trait in individual i from the population, and  is the 
population mean or constant. Assuming that A, D, C and E are independent with no 
covariance between each other, the variance of the trait then consists of the variances of A, D, 
C and E: 
Var(X)=Var(A) + Var(D) + Var(C) + Var(E) 
Therefore, the proportion of variance of each latent variable represents the influence of 
genetic or environmental factors on the trait. For example, the relative influence of additive 





In twin analysis, however, it is not possible to estimate C and D simultaneously because the 
information from twins is not sufficient to estimate all the A, D, C and E parameters in the 
same model. A convenient way is to estimate ADE model and ACE model separately, to 





5 SUMMARY OF INDIVIDUAL STUDIES 
5.1 STUDY I: ASSOCIATION BETWEEN ASTHMA AND ADHD 
5.1.1 Background 
Several studies have assessed the possible association between asthma and ADHD, but 
evidence from published studies is inconclusive as no previous original studies or meta-
analyses adequately addressed the potential effects from important confounders.95,96,207,208 
Therefore, the hypothesis of a direct link between asthma and ADHD needs to be rigorously 
investigated. To fill this knowledge gap, we first conducted a comprehensive systematic 
review and meta-analysis of the cross-sectional association between asthma and ADHD on 
published and unpublished data. We then validated the results from the meta-analysis in a 
Swedish population-based cohort study while addressing the role of confounding for this 
association. 
5.1.2 Methods 
5.1.2.1 Systematic review and meta-analysis 
We searched databases including PubMed, PsycINFO, Embase, Embase Classic, Ovid 
MEDLINE, and Web of Knowledge databases (Web of Science [Science Citation Index 
Expanded], Biological Abstracts, BIOSIS, and Food Science and Technology Abstracts) for 
 
Figure 5.1.2.1 Flow diagram of identifying individual studies for meta-analysis. 
* References of excluded studies, with reasons for exclusion, are reported in the appendix. 
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publications up to Oct 31, 2017, without any restrictions on language, date, or article type. 
Observational studies investigating the association between asthma and ADHD were 
included, but we excluded studies with less than ten participants per group. More details of 
search strategies and inclusion/exclusion criteria can be found in the publication of Study I.209 
The flow diagram of identifying individual studies is shown in Figure 5.1.2.1. Quality of 
studies were rated according to the Newcastle-Ottawa Scale.210 
We used random-effect models considering that the population effect sizes may vary among 
studies. Different studies were weighted by the reciprocal of the variance of the effect size. 
The primary analysis pooled unadjusted ORs from cross-sectional studies (or data from 
longitudinal studies at baseline) with lifetime or current prevalence (as available) of ADHD 
and asthma (when data on both lifetime and current asthma or ADHD prevalence were 
available in the same study, data related to the lifetime prevalence were considered for the 
primary analysis). The secondary analysis pooled adjusted ORs from cross-sectional studies. 
We tested the heterogeneity across studies using the I2 index, and Egger’s test and funnel 
plots to estimate potential publication bias. 
5.1.2.2 Swedish population-based cohort study 
We first created a list of all covariates used in the individual studies of our systematic review. 
We then used a DAG (Figure 5.1.2.2) to visually depict the association between asthma and 
ADHD, considering all covariates that were mentioned in the individual studies and could be 
identified through Swedish registers. The covariates were categorized as confounders 
(common causes of asthma and ADHD), mediators (covariates lying on the causal pathway 
from asthma to ADHD), and colliders (common results of asthma and ADHD). More details 
 
Figure 5.1.2.2 DAG for the association between asthma and ADHD. 
Age and sex are not presented in the figure, but adjusted in the model. 
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on the rationale of covariates categorization can be found in the supplementary file in the 
publication of Study I.209 To estimate the adjusted OR, we adjusted only for covariates that 
were classified as potential confounders in the directed acyclic graph because adjustment for 
mediators and colliders can introduce bias.171 
5.1.3 Results 
5.1.3.1 Meta-analysis 
Studies included in the meta-analysis pooled together 210 363 individuals with ADHD and 3 
115 168 without. The primary analysis indicated a significant association between asthma 
and ADHD (pooled unadjusted OR 1.66; 95% CI, 1.22–2.26), although with high 
heterogeneity (I2=99.47), and possible publication bias indicated by Egger’s test (p=0.049). 
The pooled adjusted OR was similar (OR 1.53; 95% CI, 1.41–1.65; Figure 5.1.3.1); although 
still with potentially high heterogeneity (I2=50.76) and possible publication bias (p=0.026 in 
Egger’s test). 
5.1.3.2 Swedish population-based study 
We included 1 575 377 individuals in the Swedish population-based cohort study, of whom 
259 253 (16.5%) had asthma and 57957 (3.7%) had ADHD. Asthma was significantly 
associated with ADHD (OR 1.60; 95% CI 1.57–1.63), and the association remained 
significant after adjusting for all potential confounders (OR, 1.45; 95% CI, 1.41–1.48). 
5.2 STUDY II: FAMLIAL LIABILITY TO ASTHMA AND ADHD 
5.2.1 Background 
In a recent meta-analysis, we found a significant association between ADHD and asthma,209 
but underlying mechanism of the association is still unknown. Asthma and ADHD are both 
highly heritable disorders.44,211 A large genome-wide association meta-analysis54 of ADHD 
 
Figure 5.1.3.1 Forest plot of adjusted ORs. 
This analysis only included cross-sectional studies with lifetime or current prevalence estimates of 
asthma (if both were available, lifetime estimates were used). 
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reported a small genetic correlation with asthma, but the extent to which these findings 
replicate in family and twin data remains unclear. Findings from early clinically-based sibling 
studies212,213 and twin studies214,215 were inconclusive due to limited statistical power and 
incomplete clinical diagnosis information. To fill these gaps, we used the nationwide Swedish 
register data to investigate the shared familial liability to asthma and ADHD, and to conduct 
the first twin study using clinically diagnosed asthma and ADHD to estimate the relative 
contribution of genetic and environmental influences to the association. 
5.2.2 Methods 
The main cohort including 927 956 individuals born between 1992 and 2001 in Sweden was 
identified from MBR. We extracted all possible pairs of MZ and DZ twins, full-siblings, 
maternal and paternal half-siblings and full- and half-cousins for the familial co-aggregation 
analysis; unique MZ and DZ twin pairs were used for the twin modelling analysis. 
5.2.2.1 Familial co-aggregation analysis 
Using logistic regression models, we estimated the ORs of having ADHD in individuals 
(outcome person) whose relatives (exposure person) had asthma compared to individuals 
whose relatives did not have asthma. Existence of familial liability can be inferred by the 
different magnitude of associations in different degrees of siblings.176,216 To test the 
alternative explanation of direct causality underlying the association instead of shared 
familial liability, we conducted sensitivity analyses adjusting asthma in the outcome person 
when ADHD was the outcome, and adjusting ADHD in the outcome person when asthma 
was the outcome. 
5.2.2.2 Twin modelling analysis 
We calculated the intra-class (ICCs, correlations of the same trait across twins) and cross-
twin-cross-trait (CTCT, correlations of trait one in sibling one and trait two in sibling two) 
correlations. In the bivariate twin modelling, we first fitted a saturated model on means, 
variances and correlations, including sex and year of birth as covariates. Sub-models 
including ACE, ADE and AE models were then fitted to estimate the parameters for A, D, C 
and E. 
5.2.3 Results 
5.2.3.1 Familial co-aggregation analysis 
The pattern of associations across twins, siblings and cousins indicated familial liability and 
genetic influences as the association being strongest in MZ twins (OR, 1.67; 95% CI, 0.99-
2.84) and attenuating by genetic relatedness. Sensitivity analyses adjusting for the exposure 
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disorder in the outcome person further supported the underlying familial liability, although 
the association slightly attenuated from the main analysis. 
5.2.3.2 Twin modelling 
The ICCs for asthma and ADHD were higher among MZ twins than DZ twins. CTCT was 
also higher among MZ twins (0.13; 95% CI, 0.07-0.19) than DZ twins (0.08; 95% CI, 0.03-
0.13). In twin modelling, ACE model was the best fiting model with the lowest AIC value. 
The phenotypic correlation between asthma and ADHD was 0.09 (0.05-0.14) and the genetic 
correlation was 0.12 (0.02-0.21). Univariate estimates and correlation coefficients are 
illustrated in Figure 5.2.3.2. Genetic factors explained most of the phenotypic correlation 
(0.88; 0.30-1.46). Estimates for shared and non-shared environmental factors were not 
statistically significant. 
5.3 STUDY III: ADHD AND PREMATURE DEATH 
5.3.1 Background 
Individuals with ADHD present higher risks of adversities that correlate with premature 
death, including conduct disorder (CD),130,217 substance use disorders (SUD),218,219 injuries134 
and suicidal behaviors.138 However, little is known about if ADHD is directly associated with 
premature death and if psychiatric comorbidities would affect the association. A Danish 
 
Figure 5.2.3.2 Path parameter estimates for the ACE model presented for one 
twin. 
The figure illustrates cross-trait paths within one individual. Rectangles in the bottom indicate total 
variances for asthma and ADHD, standardized to the fixed value of 1. Circles represent different latent 
variables of A, C and E, each having a variance of 1. Numbers under the square root signs represent the 
percentage of variance accounted by each component for asthma and ADHD, respectively. Curved 
double arrows above indicate correlations between A (rA), C (rC) and E (rE) across asthma and ADHD. 
Within parentheses are 95% confidence intervals of estimated parameters. 
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register-based study reported increased all-cause mortality risks in ADHD, with unintentional 
injury as the leading cause of death.143 The authors also found that the association was 
stronger when comorbid CD and/or SUD were present. Nonetheless, cause-specific mortality 
risks and potential roles of various psychiatric comorbid disorders remained unclear. In Study 
III, we investigated if ADHD was associated with all-cause and cause-specific mortality 
risks, and explored if number and type of psychiatric comorbidities (early-onset vs later-onset 
comorbid psychiatric disorders) would affect the association. 
5.3.2 Methods 
We obtained the study cohort from MBR, including all individuals born in Sweden between 
1983 and 2009, who were alive and residing in Sweden on their 1-year birthday or January 1, 
2001 (from when outpatient data was available), whichever came later. We followed the 
cohort up until death, emigration, or December 31, 2013 (whichever came first). We used 
Cox proportional hazard regression models to estimate the mortality risks, with attained age 
as the underlying time-scale. ADHD was the main exposure. ADHD and psychiatric 
comorbidities were treated as time-varying variables. 
5.3.2.1 ADHD and risk of premature death 
We compared the all-cause and cause-specific mortality risks between individuals with and 
without ADHD, and then separately analyzed the association in childhood and adulthood to 
test the potential effects of having ADHD in different age groups. 
5.3.2.2 Psychiatric comorbidity with ADHD and risk of premature death 
Since death events in childhood were limited, this analysis was restricted to adults. First, we 
analyzed if number (0, 1, 2, 3, or ≥4) of psychiatric comorbidities would affect the mortality 
risks, comparing individuals with and without ADHD. Second, we looked at the mortality 
risks of having each specific psychiatric comorbidity within the ADHD group. Last, we 
investigated how early-onset and later-onset psychiatric comorbidities affected all-cause as 
well as cause-specific mortality risks by comparing individuals with and without ADHD. 
This was done by stepwise adjusting early-onset and later-onset psychiatric comorbidities. 
5.3.3 Results 
Unintentional injuries and suicide were the leading causes of death in ADHD. We found that 
ADHD was significantly associated with all-cause mortality risks (HR, 3.94; 95% CI, 3.51-
4.43) and the association was much stronger in adulthood (4.64; 4.11-5.25) compared with 
childhood (1.41; 0.97-2.04); higher  number of psychiatric comorbidities with ADHD 
presented higher risks of premature death (HR for individuals with only ADHD, 1.41 [95% 
CI, 1.01-1.97]; HR for those with ≥4 comorbidities, 25.22 [95% CI, 19.60-32.46]). 
Among adults, individuals with ADHD presented higher mortality rates due to natural causes 
compared to those without ADHD (3.44 vs. 1.13 per 10 000 person-years; Table 5.3.3) and 
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the association was significant before adjusting for any psychiatric comorbidity (HR, 2.68; 
95% CI, 1.95-3.67). However, the association attenuated to non-significant when early-onset 
psychiatric disorders were further adjusted in the model (HR, 1.32; 95% CI, 0.94-1.85). For 
unnatural cause-specific mortality risks, the association was stronger (HR, 5.93; 95% CI, 
5.17-6.81), and slightly attenuated when adjusting for early-onset comorbidities (HR, 5.33; 
95% CI, 4.59-6.20), but attenuated substantially when adding later-onset comorbidities in the 
model (HR, 1.57; 95% CI, 1.35-1.83). Moreover, the association remained significant for 
unintentional injuries (HR, 2.14; 95% CI, 1.71-2.68) and other external causes (HR, 1.75; 
95% CI, 1.23-2.48), but not for suicide (HR, 1.13; 95% CI, 0.88-1.45). 
5.4 STUDY IV: ADHD MEDICATION AND PREMATURE DEATH 
5.4.1 Background 
ADHD is associated with increased mortality risks, especially due to unnatural causes 
including suicide and unintentional injuries.143,220 ADHD medication treatment has been 
reported with efficacy in not only alleviating core symptoms of ADHD, but also decreasing 
the risks of adversities including SUD, depression, suicide, and injuries.149 However, it is 
unclear how ADHD medication would affect the mortality risks in individuals with ADHD. 
Also, various factors such as concern over side effects and long-term efficacy hinder the 
initiation and continuation of ADHD medication,221-225 leaving the disorder being under 
treated in most countries including Sweden.226-229 In Study IV, we investigated how initiation 
and continuation of ADHD medication associated with all-cause and cause-specific mortality 
risks in individuals with ADHD, to provide evidence of great clinical relevance for guiding 
management of ADHD after diagnosis. 
5.4.2 Methods 
 
Figure 5.3.3 Early- and later-onset psychiatric comorbidity with ADHD and risk of 
premature death in adults. 
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We obtained a cohort of 68 493 individuals born between 1973 and 2009, diagnosed with 
ADHD between January 01, 2007 and December 31, 2013 using linkage of Swedish national 
registers, and followed them from ADHD diagnosis until death, emigration or up to two 
years. Cohort selection and sample sizes are shown in Figure 5.4.2.1. We separately 
investigated the potential effects from ADHD medication initiation and continuation on all-
cause and cause-specific death. Deaths due to natural causes were limited and we did not 
analyze the association for natural cause-specific mortality risks. Follow-up setting for the 
initiation and continuation analysis is illustrated in Figure 5.4.2.2. Between-individual Cox 
regression models were used to compared the mortality risks between the treated and 
untreated person-times. 
5.4.2.1 Initiation analysis 
We used the main cohort and looked at the all-cause and unnatural cause-specific mortality 
risks between individuals who initiated vs. who did not initiate ADHD medication treatment 
at ADHD diagnosis. The follow-up was censored at the first switch of treatment status, so 
that we only compared the treatment vs. non-treatment person-times right after ADHD 
diagnosis. 
5.4.2.2 Continuation analysis 
We identified a sub-cohort with individuals who were continuously medicated at least 3 
months, with follow-up starting from 3 months after ADHD medication initiation. Follow-up 
time was reset to zero when the medication was re-started after discontinuation, so that we 
compared only the continuation and discontinuation person-times. 
5.4.2.3 Sensitivity analysis 
 




We tested if the treatment effects were time-varying or stable across prolonged treatment 
periods by censoring follow-up at 6 months and 1 year, respectively. For the continuation 
analysis, we re-ran the analysis among those who were continuously treated for at least 6 
months, to test if longer treatment before continuation would differ from shorter treatment. 
5.4.3 Results 
5.4.3.1 ADHD medication initiation 
The mortality rates among those who initiated medication treatment at ADHD diagnosis were 
lower than those who did not initiate medication, with the association being statistically 
significant for all-cause (adjusted HR [aHR], 0.31; 95% CI, 0.13-0.73) and unnatural cause-
specific (aHR, 0.33; 95% CI, 0.14-0.80) morality risks. However, the associations were not 
significant for specific unnatural causes including suicide (aHR, 0.56; 95% CI, 0.16-1.96) and 
 
Figure 5.4.2.2 Follow-up setting for the initiation and continuation analysis 
The figure shows how we set the time and follow-up for initiation and continuation analysis (with maximum 
follow-up of 2 years). 
a. Initiation analysis: Different rows represent different individuals. Time zero was the time of cohort entry (time 
of ADHD diagnosis). Follow-up started at ADHD diagnosis, and ended at death, emigration, censoring up until 
2 years of follow-up, or whenever the treatment status changed. For example, individual A started follow-up as 
initiating medication treatment at ADHD diagnosis, and then censored when A stopped medication. Follow-up 
beyond 2 years were censored and not included in the analysis (such as individual D). 
b. Continuation analysis: Different rows may represent different continuation/discontinuation periods of the 
same individual. Time zero was either 3 or 6 months after the first medication prescription, or every time when 
the individual re-started medication after a period of discontinuation. Therefore, the initial 3 or 6 mongths of 
medication periods were excluded from analysis. Follow-up stopped at death, emigration, up until 2 years of 
follow-up, or whenever the individual re-started medication treatment. For example, individual G started follow-
up with a period of continuing medication treatment (indicated as G1 in the figure), followed by a period of 
discontinuation.  Then the re-start of medication period was treated as another observation (indicated as G2), 
until censored. Maximum time of censoring was 2 years after start of follow-up (such as individual I). 
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unintentional injuries (aHR, 0.23; 95% CI, 0.05-1.10), although the mortality rates were also 
much lower in the treated group compared to the un-treated group. 
5.4.3.2 ADHD medication continuation 
Medication continuation was associated with substantially lower all-cause (aHR, 0.37; 95% 
CI, 0.24-0.57) and unnatural cause-specific (aHR, 0.42; 95% CI, 0.27-0.66) mortality risks 
compared to discontinuation. The associations remained statistically significant for specific 
unnatural causes including suicide (aHR, 0.45; 95% CI, 0.21-0.96) and unintentional injuries 
(aHR, 0.47; 95% CI, 0.23-0.96). 
5.4.3.3 Sensitivity analysis 
Results of censoring at 6 months and 1 year were similar to the main analysis when censoring 
at 2 years, although there were fewer death events, and no death due to unintentional injuries 
among the treated group when censoring at 6 months. Among those who were treated at least 




In this thesis work, we investigated the magnitude and potential mechanisms of the 
associations between ADHD and specific adverse outcomes including asthma and premature 
death using national register-based data in Sweden. In Study I and II, we found a robust 
association between asthma and ADHD, and the association was largely explained by shared 
genetic overlaps. In Study III and IV, we found that individuals with ADHD presented 
substantially increased risk of premature deaths with psychiatric comorbidities contributing to 
most of the excessive risks, and that ADHD medication may help lower the mortality risks. 
Our findings provided evidence for further research into ADHD related adverse outcomes, 
and have both clinical and public health implications for preventing or alleviating the burden 
of specific adversities.   
6.1 ADHD AND ASTHMA 
6.1.1 Main findings 
In Study I, we combined a meta-analysis with a national population-based cohort study and 
tested the cross-sectional association between asthma and ADHD. The pooled unadjusted and 
adjusted ORs from the meta-analysis supported previous findings of the association,95,96 and 
the results were robust across study settings. To clarify the potential confounding that most 
previous studies did not fully address, we summarized all covariates adjusted for in previous 
studies, systematically assessed their potential roles given the possible causal pathways 
between asthma and ADHD using a DAG, and then conducted the new population analysis 
by only adjusting for those categorized as confounders. The adjusted OR from the population 
study was comparable with the meta-analysis, providing more concrete evidence of the link 
between asthma and ADHD.  
In Study II, we investigated the familial liability to asthma and ADHD, and used a twin 
modelling analysis to quantify the genetic and environmental influences as well as the genetic 
correlations. For the first time, we found that relatives of probands diagnosed with either 
asthma or ADHD have elevated risk of being diagnosed with the other. This was not 
consistent with previous sibling analyses that did not find evidence of familial co-aggregation 
between asthma and ADHD,212,213 but statistical power in these two studies was extremely 
limited. Results from our twin modelling analysis indicated that the association between 
asthma and ADHD may be substantially explained by shared etiology, especially shared 
genetic risk factors, which was also supported by the pattern of associations across relatives 
in our familial-coaggregation analysis. The genetic correlation between asthma and ADHD 
estimated from our twin modelling was weak but robust and similar with results from a 
GWAS finding.54 The size of the genetic correlation between these two highly heritable 
conditions indicate that only a small proportion of the total genetic underpinnings of asthma 
and ADHD is shared across disorders. 
6.1.2 Interpretations and implications 
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Findings from Study I and II have important clinical and public health implications for both 
disorders, as well as for future research. The health burden attributed to asthma and ADHD is 
tremendous worldwide. Delayed diagnosis remains to be a challenge for both, and early 
detection and management predicted better prognosis.131,132,230-232 Currently, practitioners 
dealing with asthmatic children and not aware of the link between asthma and ADHD may 
consider comorbid inattention, hyperactivity and impulsivity as asthma symptomatology or 
results from asthma treatment,213 or a consequence of a psychological distress due to the fact 
of having a chronic medical condition,91,233,234 thus missing an important opportunity to 
identify a neuropsychiatric condition for which effective treatments are available.82,149,235 
With improved awareness of the link between asthma and ADHD, clinicians can make more 
prompt decisions of referral for children with one disorder presenting suspicious symptoms of 
the other. Apart from within-individual presentation, family history of the other disorder can 
also serve as a sign of clinical referral due to the familial liability identified from Study II. 
For instance, practitioners seeing patients referred for ADHD, should query about personal 
and family history of symptoms of asthma, which may pin to the need of a prompt referral for 
specialist assessment of asthma, thus reducing the diagnostic delay for this condition. Our 
findings emphasize the importance of joint services where clinicians with expertise in 
developmental psychopathology and those specialized in allergic/atopic conditions may 
quickly and effectively interact to provide timely and high-quality care to patients with the 
double burden of developmental disorders (such as ADHD) and medical conditions (such as 
asthma). As a result, early diagnosis and treatment can substantially help with lowering the 
overall health burden improving the prognosis for both diseases. Although it is currently not 
feasible to prevent the onset of asthma and ADHD, early intervention and effective treatment 
of the disruptive behaviors related to ADHD symptoms among asthmatic children, for 
example, may improve the adherence to asthma treatment, as to decreasing the unnecessary 
health-care costs. Early diagnosis and treatment of ADHD, on the other hand, may 
substantially improve the quality of life and prevent severe adversities such as psychiatric 
comorbidities and premature deaths. 
6.2 ADHD AND PREMATURE DEATH 
6.2.1 Main findings 
In Study III, we for the first time investigated the cause-specific mortality risks associated 
with ADHD, and explored the potential effects from number and types of psychiatric 
comorbidities. We found that ADHD in adulthood, later diagnosis of ADHD and more 
comorbid psychiatric comorbidities presented even higher mortality risks. Among adults, 
early-onset psychiatric comorbidities including ASD, ID and CD may explain most of the 
mortality risks due to natural deaths. For example, comorbid ADHD and ID had higher 
mortality risks compared to ADHD alone, and most deaths among individuals with such 
comorbidity were due to natural deaths. This was consistent with previous findings, with the 
possible explanation that ID related poor health behavior and self-care may impose the risk of 
preventable diseases such as respiratory infections and digestive diseases.236,237 Comorbid 
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ADHD symptoms may further aggravate such effects. Later-onset psychiatric comorbidities 
such as SUD, depression, anxiety and schizophrenia, on the other hand, substantially 
explained the excessive mortality risks due to unnatural causes including suicide and 
unintentional injuries. Although ADHD was still associated with over 50% of increased 
unnatural cause-specific mortality risks after adjusting for all psychiatric comorbidities, the 
association largely attenuated for unintentional injuries and became non-significant for 
suicide. The twice higher risk of premature death due to unintentional injuries after adjusting 
for all psychiatric comorbidities may be explained by inattention and impulsivity symptoms 
in ADHD increasing the proneness to risky behaviors and the risk of severe unintentional 
injuries.238,239 
In Study IV, we found that ADHD medication treatment was associated with lower mortality 
risks due to unnatural causes. Individuals who initiated ADHD medication treatment at 
diagnosis had lower all-cause and unnatural cause-specific mortalities compared to those who 
did not initiate medication, although the associations were not statistically significant for 
suicide and unintentional injuries in the main analysis. Previously there were concerns over 
ADHD medication regarding side-effects involving severe events such as sudden death and 
cardiovascular events which may increase the risk of premature death, 222,223,240 but no 
previous study reported statistically significant associations. Our results provided evidence 
against such concerns over potential side-effects as an important factor impeding initiation of 
ADHD medication.241 Moreover, the mortality risks due to both suicide and unintentional 
injuries decreased by about 60% when comparing periods of medication treatment 
continuation with periods of discontinuation in our data. There have been controversies about 
whether and when to stop ADHD medication after a period of treatment due to concerns over 
long-term tolerance and decreased efficacy.69,242,243 Our results were not in line with such 
concerns regarding premature death, with similar treatment benefits among individuals 
medicated for at least 3 months to those medicated for at least 6 months. Furthermore, we did 
not find an obvious decline of benefits from longer treatments up to 2 years, which is also 
evidence against the concern of decreased effectiveness after longer-term medication use. 
6.2.2 Interpretations and implications 
Results from Study III and IV indicate that individuals with ADHD suffer from increased risk 
of premature death, with different types of psychiatric comorbidities exerting different effects 
on the association. ADHD medication may be a possible way to lower the excessive mortality 
risks. Identification of psychiatric comorbidities, as well as proper initiation and continuation 
of medication treatment may help to prevent premature death in ADHD. Among specific 
psychiatric comorbidities, we found from Study III that comorbidity with SUD, depression, 
anxiety and bipolar disorders presented specifically higher risk of dying from suicide 
compared to ADHD only. Co-occurrences of ADHD and these disorders should then be 
prioritized for treatment in order to prevent suicide. Moreover, individuals with comorbid 
ADHD and ID presented lower risk of unintentional injuries probably due to the limited 
possibility of obtaining a driving license. Considering the increased risk of natural death 
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associated with early-onset psychiatric comorbidities, management of such comorbidities 
including ID may prioritize closer monitoring of somatic health conditions to prevent natural 
deaths. Undertreatment of ADHD remains a severe issue in most countries including Sweden 
(e.g., some patients with ADHD are not prescribed with ADHD medication treatment for a 
considerable amount of time after diagnosis),226-229 and medication discontinuation rates are 
high among individuals with ADHD (i.e., rates reported as ranging from 13% to 64%244), 
which may have a negative impact on the prognosis.16 In Study IV, almost 40% of cohort 
members did not initiate ADHD medication until about 5 months after ADHD diagnosis. A 
study among children and adolescents reported that longer interval between the first ADHD 
diagnosis and the first prescription of methylphenidate was associated with higher all-cause 
mortality risks, although the authors did not analyze the treatment effects of medication per 
se and did not have sufficient statistical power to investigate cause-specific mortality risks.245 
Nonetheless, our results in Study IV did point out that proper ADHD medication treatment 
may help alleviating the excessive mortality risks associated with ADHD and preventing 
premature deaths among individuals with ADHD. 
6.3 STRENGTHS AND LIMITATIONS 
6.3.1 Strengths 
Studies in this thesis work provided significant evidence on clearly defined research 
questions with both research and clinical/public health relevance. Our findings could facilitate 
the understanding of both the magnitude and mechanisms of specific associations between 
ADHD and specific adverse outcomes, and have important implications for preventing severe 
adversities. Large scale data sets based on national registers were extracted with 
prospectively collected information on socioeconomic data and health related information for 
cohort members. Thoroughly designed analysis plans generated robust results with causal 
inference frame work considered by adjusting for relevant covariates in the statistical models. 
Previous studies provided controversial findings regarding the association between asthma 
and ADHD, and available meta-analyses with limited evidence could not provide conclusive 
results and failed to address potential confounders that may bias the association. In Study I, 
our meta-analysis included 49 studies and substantially extended the evidence on an 
association between asthma and ADHD from previous meta-analyses. Meta-regression 
showed that the pooled estimates were robust across study settings, year of study, participants 
age distribution and study continent. We also obtained unpublished data by contacting 
authors of the included studies and therefore gathered more evidence. More importantly, we 
were able to systematically assess the potential confounding and adjust for possible 
confounders in the Swedish national register-based population analysis, providing a 
rigorously validated link between asthma and ADHD on the population level. In Study II, we 
obtained the largest family data ever used to investigate the familial liability to asthma and 
ADHD, and were able to quantify the genetic overlaps between clinically diagnosed asthma 
and ADHD for the first time. The findings of shared genetic overlaps also provided important 
implications for future research on not only the biological pathways between ADHD and 
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asthma or other allergic conditions in general, but also other observed somatic comorbidities 
with ADHD such as obesity or clinically diagnosed eating disorders. 
Evidence on ADHD associated mortality risks had been scarce as the relatively low incidence 
of premature death among individuals with ADHD requires large sample size with long-term 
follow-up. Furthermore, no previous studies had the resources to clarify the cause-specific 
mortality risks and the potential roles of various psychiatric comorbidities. Our work in Study 
III and IV largely improved the understanding of the all-cause and cause-specific mortality 
risks associated with ADHD. By identifying different number and types of psychiatric 
comorbidities, and adjusting for them in a stepwise manner in Study III, we were the first to 
clarify the potential mediating effects from specific comorbidities on specific death causes. In 
Study IV, we were also the first to have the data for investigation of the specific effects from 
ADHD medication treatment initiation and continuation on cause-specific mortality risks in 
ADHD, providing significant results for guiding clinical practice. We adopted a new-user 
design, and tested if the potential treatment effect was time-varying or time stable, as well as 
if longer treatment presented different results compared to shorter treatment before 
discontinuation. We also conducted multiple sensitivity analyses in both Study III and IV to 
test the robustness of our results and to extend the generalizability of our findings. 
6.3.2 Limitations 
There were limitations in each study of the thesis work that should be taken into 
consideration when interpreting the findings. Although with large sample size and 
comprehensive information, the Swedish national registers do not always have perfect 
coverage and may have the issue of misclassification. For instance, the prevalence of ADHD 
is usually underestimated in the register data as individuals with mild ADHD may not always 
seek for professional help at all or until the symptoms and impairments became severe 
enough, resulting in either misclassification or delayed diagnosis. Moreover, diagnosis from 
NPR were mostly recorded in outpatient register which was initiated in 2001, and we do not 
have data on medication treatment before the start of PDR from July, 2005. There are also 
other specific limitations in each study that should be mentioned. 
In Study I, heterogeneity across the studies included in the meta-analysis was significantly 
high, indicating that the overall pooled estimation may not appropriately represent all 
individual studies, although heterogeneity decreased in the sub-group analyses. Publication 
bias was detected, and the quality rating for some studies indicated poor representativeness. 
In the population-based analysis, false-negative misclassification was possible among those 
without diagnosis of asthma or ADHD, although this may have underestimated the 
association instead of overestimation. Furthermore, we did not aim to test the longitudinal 
association between asthma and ADHD in either the meta-analysis or the population-based 
analysis. The main reason is that asthma as a somatic condition with more noticeable 
symptoms may usually precede ADHD in diagnosis, but this temporality does not necessarily 
mean later ADHD associated with early asthma should be interpreted as a causal link. 
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In Study II, we could not completely rule out the possibility of direct causality between 
asthma and ADHD, since the overall association and phenotypic correlation was weak in 
magnitude and we could not make conclusive judgements on the environmental contributions 
to the comorbidity. In fact, we did observe slightly attenuated ORs when adjusting for asthma 
or ADHD in the outcome person in the familial co-aggregation analysis and a weak and non-
significant correlation for non-shared environmental factors in the ACE model, indicating 
possibly weak causality between asthma and ADHD. The previously raised hypothesis of 
asthma and other allergic reactions producing inflammatory cytokines and then affecting the 
development of ADHD may be possible and should be tested in more appropriately designed 
experiments.92,246 Vertical pleiotropy from the same genes is also possible, as the genetic 
variants causing allergic conditions, and then ADHD, with possible mediation of the 
inflammatory pathophysiology. 
In Study III, we could not fully address the cause-specific mortality risks in childhood due to 
limited death events, and we had to restrict the analysis of psychiatric comorbidities among 
adults. The follow-up window in our data was relatively short, and we should rely on future 
studies with even larger sample size and longer follow-up window to investigate this issue in 
childhood. While investigating the mortality risks, we did not account for ADHD medication 
treatment. Considering the reported benefits of ADHD medication treatment on adversities 
associated with premature death,149 the true mortality risks caused by ADHD may be even 
larger than reported in our data. 
In Study IV, the number of death events were limited in most of our analyses, which may 
explain some of the non-significant associations. Second, unmeasured confounding may have 
important contributions to the results. Larger differences in disease severity between the 
treated and un-treated groups may have masked the potential treatment benefits in the 
initiation analysis, although this may have been less of an issue in the continuation analysis. 
Third, we did not investigate specific reasons of medication initiation or discontinuation. 
Contraindications of both initiating and continuing ADHD medications such as psychiatric or 
somatic conditions may also be important confounders. Fourth, the current results did not 
address questions regarding long-term treatment effects of ADHD medication, for example if 
baseline treatment or extended cumulative treatment associates with mortality risks years 
later.149 
For both Study III and IV, deaths due to natural causes were rarer compared to unnatural 
deaths, making it difficult to further clarify the specific natural causes such as infectious or 
nervous system diseases in Study III, or to investigate the treatment effects on natural cause-
specific mortality risks in Study IV. However, unnatural deaths consistently accounted for 
most of the deaths and mortality risks in ADHD, indicating that management on adversities 
associated with unnatural deaths should be prioritized. Moreover, as observational studies, 
our work may not be interpreted as established causal effects from ADHD or ADHD 
medication treatment on mortality risks. For example, an alternative explanation for the 
reduced mortality risks during continued medication treatment might be better adherence to 
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general health service and better self-control and management in individuals undergoing 
persistent medication. 
6.4 ETHICAL CONSIDERATIONS 
The studies conducted as above used individual level information on personal history of birth, 
education, occupation, emigration, health and death identified and extracted from Swedish 
national registers. The unique PIN we used to link through different registers was encoded by 
register holders and designated to each individual in our cohorts, and it is not possible for 
researchers to track back to the individual’s personal identity. Linkage of data across registers 
obtained approval by the Regional Ethical Review Board in Stockholm in 2013 and the 
approval will be updated as required. Regardless of this fact, an ethical issue may occur since 
according to the previously valid Personal Data Act in Sweden (PUL) and the recently 
adopted European General Data Protection Regulation (GDPR), register data is still sensitive 
personal data, and strict rules should be obeyed to while conducting relevant research. 
While forming a research question and gathering the data for analysis, potential gains 
regarding the positive implications from the study findings are always weighed against 
potential harms, and only the most relevant information to the research questions were 
extracted and analyzed. We were specifically careful in reporting our results, pointing out 
both strengths and limitations of our work, and we did not impose any interpretations of our 
results to be stigmatizing for specific groups of individuals. For example, we found a 
population-level association between asthma and ADHD, but this conclusion does not mean 
all individuals with asthma will develop ADHD or vice versa. Also, the identified genetic 
overlap between the two disorders does not justify the possible prejudice that asthma and 
ADHD would definitely co-aggregate in the family. Our intention and focus were to 
emphasize the awareness of the link between two of the mostly diagnosed diseases in 
childhood and therefore to tackle the challenge of delay in diagnosis and associated health 
burden. In Study III, our findings indicate individuals with ADHD may suffer from increased 
risk of premature death due to suicide, but this should never be interpreted as ADHD would 
definitely lead to suicide death, nor to imply social stigma of risky behavior and higher risks 
of having other psychiatric comorbidities on individuals with ADHD. Again, the focus was to 
improve the awareness of the issue, so as to attract more proper resources to prevent 
premature deaths. Such considerations and interpretations were presented both in the 
constituent papers and the communicating materials when interviewed by public media. 
Another issue that may also jeopardize integrity of the research, which may exist in any 
projects in academic world, is the possibility of any form of misconduct. Throughout the 
thesis work, source datasets were anonymized and maintained on a protected server. Data 
extraction and analysis process were documented according to the data management and 





In summary, findings from this thesis work support that individuals with ADHD are at 
increased risk of adverse outcomes including somatic conditions such as asthma and severe 
adversities such as premature death. Shared genetic factors largely explained the association 
between asthma and ADHD, indicating the significance of detecting within-individual and 
family history of either disorder for preventing delayed diagnosis of the other condition. This 
also shed light on the general link between allergic or inflammatory conditions and 
psychiatric disorders, and provided a possible way to understand the etiology of comorbidity 
between ADHD and other somatic diseases. Moreover, psychiatric comorbidities and 
medication treatment play crucial roles in understanding the mechanisms of ADHD 
associated mortality risks. Identification of specific psychiatric comorbidities and 
implementing proper treatment strategies should be prioritized in preventing premature 
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